Controversies in the treatment of high-risk prostate cancer - What is the optimal combination of hormonal therapy and radiotherapy: A review of literature
BACKGROUND. In high-risk prostate carcinoma, there is controversy whether these patients should be treated with escalated-dose (≥74 Gy) or conventional-dose radiotherapy (<74 Gy) combined with hormonal therapy. Furthermore, the issue of the optimal duration and timing of hormonal therapy are not well crystallized. PATIENTS AND METHODS. A search for evidence from randomized- and large nonrandomized studies in order to address these issues, was therefore initiated. For this purpose, MedLine, EMbase, and PubMed and the data base of the Dutch randomized dose-escalation trial, were consulted. RESULTS AND CONCLUSIONS. From this search it was concluded that the benefit of hormonal therapy in combination with conventional-dose radiotherapy (<74 Gy) in high-risk prostate cancer is evident (Level 2 evidence); Levels 2 and 3 evidence were provided by several studies supporting the use of escalated-dose radiotherapy in high-risk prostate cancer. For the combination of hormonal therapy with escalated-dose radiotherapy in these patients, there is Level 2 evidence for moderately escalated dose (74 Gy) and high escalated dose (≥78 Gy). The optimal duration and timing of hormonal therapy are not well defined. More randomized-controlled trials and meta-analyses are therefore needed to clearly determine the independent role of dose-escalation in high-risk patients treated with hormonal therapy and the optimal duration and timing of hormonal therapy.
|Keywords||Dose-escalation, High-risk group, Hormonal therapy, Prostate cancer, Radiotherapy|
|Persistent URL||dx.doi.org/10.1002/pros.21102, hdl.handle.net/1765/27887|
Al-Mamgani, A., Lebesque, J.V., Heemsbergen, W.D., Tans, L., Kirkels, W.J., Levendag, P.C., & Incrocci, L.. (2010). Controversies in the treatment of high-risk prostate cancer - What is the optimal combination of hormonal therapy and radiotherapy: A review of literature. The Prostate, 70(7), 701–709. doi:10.1002/pros.21102